
    
      This is a study of CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin.
      Patients are assigned to receive 4 circles of cell therapy. The safety and clinical response
      are evaluated. Biomarkers and immunological markers are also monitored.
    
  